Bloomberg Markets & Finance via Youtube

Nov.23 — A Covid-19 vaccine developed by the University of Oxford and AstraZeneca Plc prevented a majority of people from getting the disease but fell short of the high bar set by Pfizer Inc. and Moderna Inc., according to initial results of a large trial. The vaccine stopped an average of 70% of participants in a study from falling ill, an early analysis of the data show. Suzi Ring reports on “Bloomberg Markets: European Open.”

READ ALSO  Pompeo tries to pin Biden down with parting foreign policy blitz